Tonix Zeroes In On Fatigue As Go-Forward Endpoint In Long COVID
Executive Summary
The company’s Phase II POC trial did not meet the pain primary endpoint, but fatigue may be more relevant in long COVID despite the condition’s overlap with fibromyalgia.
You may also be interested in...
As Ozempic, Mounjaro Grab Share, Can Metformin Get A Leg-Up From Long COVID?
Diabetes and obesity products like Ozempic/Wegovy and Mounjaro are gaining share at the expense of metformin and SGLT-2 inhibitors. Scrip looks at data on prescription shifts in the US while examining if metformin remains attractive and whether a recent study showing efficacy in long COVID treatment could help
Virios Fibromyalgia Drug Fails Phase IIb And Firm Says COVID-19 May Be To Blame
A Phase IIb trial testing IMC-1 for fibromyalgia failed to reach statistical significance on the primary pain endpoint, but one cohort showed an improvement and Virios intends to pursue the drug further.
No End To US FDA Concerns About DEG And EG Testing, Or To OTC Firms Not Answering Its Calls
One of firms targeted in eight most recent warnings published since early September to OTC drug manufacturers, Zhao Qing Longda Biotechnology Co. in China, was dinged for both failing to respond to a request for records and for concerns about its production with DEG and EG.